{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:46:15Z","timestamp":1790268375733,"version":"4.1.0"},"reference-count":111,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Pheochromocytoma, a rare catecholamine-secreting tumor, poses significant perioperative challenges due to its potential for severe hemodynamic instability. Careful management of patients with pheochromocytoma is critical for patient safety and favorable outcomes. The diagnostic workup focuses on biochemical analysis of plasma or urinary metanephrines, followed by imaging for tumor localization and genetic testing to identify hereditary syndromes. Preoperative management emphasizes adequate alpha-adrenergic blockade followed by beta-blockade to stabilize cardiovascular function. Anesthetic planning requires meticulous attention to volume status, cardiovascular optimization, and intraoperative monitoring to mitigate the risks of hypertensive crises and hypotension. Postoperative care must account for ongoing hemodynamic and metabolic fluctuations. A multidisciplinary, protocol-driven approach is essential to improve outcomes in patients undergoing pheochromocytoma resection. This paper provides a comprehensive overview of the genetic, biochemical, clinical, and anesthetic considerations involved in the diagnosis and perioperative management of pheochromocytoma.<\/jats:p>","DOI":"10.3390\/ijms26136080","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T03:53:02Z","timestamp":1750823582000},"page":"6080","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The Perioperative Biochemical and Clinical Considerations of Pheochromocytoma Management"],"prefix":"10.3390","volume":"26","author":[{"given":"Alexa J.","family":"Gombert","sequence":"first","affiliation":[{"name":"Department of Anesthesiology, Renaissance School of Medicine, Stony Brook University, Stony Brook, NY 11794, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra M.","family":"Nerantzinis","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Renaissance School of Medicine, Stony Brook University, Stony Brook, NY 11794, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Li","sequence":"additional","affiliation":[{"name":"Renaissance School of Medicine, Stony Brook University, Stony Brook, NY 11794, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weidong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Renaissance School of Medicine, Stony Brook University, Stony Brook, NY 11794, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac Y.","family":"Yeung","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Renaissance School of Medicine, Stony Brook University, Stony Brook, NY 11794, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1816-6194","authenticated-orcid":false,"given":"Ana","family":"Costa","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Renaissance School of Medicine, Stony Brook University, Stony Brook, NY 11794, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5641-5908","authenticated-orcid":false,"given":"Sergio D.","family":"Bergese","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Renaissance School of Medicine, Stony Brook University, Stony Brook, NY 11794, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s00424-023-02793-0","article-title":"Forty years of the adrenal chromaffin cell through ISCCB meetings around the world","volume":"475","author":"Maneu","year":"2023","journal-title":"Pflugers Arch. Eur. J. Physiol."},{"key":"ref_2","first-page":"309","article-title":"Heart and catecholamines","volume":"46","author":"Prichard","year":"1991","journal-title":"Acta Cardiol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Szatko, A., Gli nicki, P., and Gietka-Czernel, M. (2023). Pheochromocytoma\/paraganglioma-associated cardiomyopathy. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1204851"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1053\/j.seminoncol.2012.11.009","article-title":"Update on the management of unusual neuroendocrine tumors: Pheochromocytoma and paraganglioma, medullary thyroid cancer and adrenocortical carcinoma","volume":"40","author":"Strosberg","year":"2013","journal-title":"Semin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jamcollsurg.2009.09.022","article-title":"Clinical spectrum of pheochromocytoma","volume":"209","author":"Guerrero","year":"2009","journal-title":"J. Am. Coll. Surg."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1210\/jc.2014-1498","article-title":"Pheochromocytoma and paraganglioma: An endocrine society clinical practice guideline","volume":"99","author":"Lenders","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_7","first-page":"159","article-title":"Pheochromocytoma and paraganglioma: From epidemiology to clinical findings","volume":"54","author":"Aygun","year":"2020","journal-title":"SiSli Etfal Hastan Tip. Bulteni\/Med. Bull. Sisli Hosp."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ijsu.2014.04.001","article-title":"Current concepts of pheochromocytoma","volume":"12","author":"Conzo","year":"2014","journal-title":"Int. J. Surg."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2478\/enr-2019-0020","article-title":"Pheochromocytoma","volume":"53","author":"Farrugia","year":"2019","journal-title":"Endocr. Regul."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.annonc.2020.08.2099","article-title":"Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO\u2013EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Fassnacht","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1097\/RCT.0b013e31829cbecf","article-title":"Serendipity in the diagnosis of pheochromocytoma","volume":"37","author":"Oshmyansky","year":"2013","journal-title":"J. Comput. Assist. Tomogr."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1245\/s10434-014-3933-x","article-title":"Clinicopathologic characteristics of incidentally identified pheochromocytoma","volume":"22","author":"Wachtel","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.5858\/2008-132-1272-PAEPU","article-title":"Pheochromocytoma and Extra-adrenal Paraganglioma: Updates","volume":"132","author":"Tischler","year":"2008","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S1470-2045(09)70204-9","article-title":"Diagnosing patients with hereditary paraganglial tumours","volume":"10","author":"Erlic","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nrc3648","article-title":"Pheochromocytoma and paraganglioma pathogenesis: Learning from genetic heterogeneity","volume":"14","author":"Dahia","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/MED.0000000000000634","article-title":"Genetics of pheochromocytoma and paraganglioma","volume":"28","author":"Wachtel","year":"2021","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes"},{"key":"ref_17","first-page":"S251","article-title":"HIF Signaling pathway in pheochromocytoma and other neuroendocrine tumors","volume":"63","author":"Zelinka","year":"2014","journal-title":"Physiol. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1055\/s-0036-1579757","article-title":"Von Hippel-Lindau Disease","volume":"5","author":"McMahon","year":"2016","journal-title":"J. Pediatr. Genet."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41574-023-00926-0","article-title":"Management of phaeochromocytoma and paraganglioma in patients with germline SDHB pathogenic variants: An international expert Consensus statement","volume":"20","author":"Perrier","year":"2024","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1093\/hmg\/2.7.851","article-title":"Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC","volume":"2","author":"Dou","year":"1993","journal-title":"Hum. Mol. Genet."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.hoc.2015.09.006","article-title":"Pheochromocytoma and Paraganglioma: Genetics, Diagnosis, and Treatment","volume":"30","author":"Fishbein","year":"2016","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1530\/EJE-12-1106","article-title":"High penetrance of pheochromocytoma in multiple endocrine neoplasia 2 caused by germ line RET codon 634 mutation in Japanese patients","volume":"168","author":"Imai","year":"2013","journal-title":"Eur. J. Endocrinol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1530\/EJE-14-0084","article-title":"Role of RET genetic variants in MEN2-associated pheochromocytoma","volume":"170","author":"Siqueira","year":"2014","journal-title":"Eur. J. Endocrinol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1089\/thy.2014.0335","article-title":"Revised american thyroid association guidelines for the management of medullary thyroid carcinoma","volume":"25","author":"Wells","year":"2015","journal-title":"Thyroid\u00ae"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1001\/jama.1997.03550010065042","article-title":"The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2","volume":"278","author":"Gutmann","year":"1997","journal-title":"JAMA"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.amjmed.2012.07.022","article-title":"Pheochromocytoma and gastrointestinal stromal tumors in patients with neurofibromatosis type I","volume":"126","author":"Vlenterie","year":"2013","journal-title":"Am. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"792","DOI":"10.4158\/EP13417.OR","article-title":"Pheochromocytoma in Neurofibromatosis Type 1: When Should it Be Suspected?","volume":"20","author":"Shinall","year":"2014","journal-title":"Endocr. Pract."},{"key":"ref_28","unstructured":"Else, T., Greenberg, S., and Fishbein, L. (2025, May 15). Hereditary Paraganglioma-Pheochromocytoma Syndromes. 21 May 2008 [Updated 21 September 2023], GeneReviews\u00ae [Internet], Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1548\/."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40842-018-0065-4","article-title":"Pheochromocytoma and Paraganglioma in Neurofibromatosis type 1: Frequent surgeries and cardiovascular crises indicate the need for screening","volume":"4","author":"Petr","year":"2018","journal-title":"Clin. Diabetes Endocrinol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s41580-019-0199-y","article-title":"mTOR at the nexus of nutrition, growth, ageing and disease","volume":"21","author":"Liu","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"E308","DOI":"10.1210\/jc.2014-2473","article-title":"Penetrance and clinical features of pheochromocytoma in a six-generation family carrying a germline TMEM127 mutation","volume":"100","author":"Toledo","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1158\/1078-0432.CCR-12-0160","article-title":"MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma","volume":"18","author":"Burnichon","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1158\/0008-5472.CAN-11-3891","article-title":"MAX and MYC: A Heritable Breakup","volume":"72","author":"Robledo","year":"2012","journal-title":"Cancer Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/ng.861","article-title":"Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma","volume":"43","author":"Schiavi","year":"2011","journal-title":"Nat. Genet."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e240269","DOI":"10.1530\/ERC-24-0269","article-title":"Phenotype of pheochromocytoma and paraganglioma by germline mutation: A Korean multicenter study","volume":"32","author":"Park","year":"2025","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ccell.2017.01.001","article-title":"Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma","volume":"31","author":"Fishbein","year":"2017","journal-title":"Cancer Cell"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1210\/endrev\/bnab019","article-title":"Personalized Management of Pheochromocytoma and Paraganglioma","volume":"43","author":"Bechmann","year":"2022","journal-title":"Endocr. Rev."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Wang, Y., Liu, B., Li, F., Zhang, Y., Gao, X., Wang, Y., and Zhou, H. (2023). The connection between tricarboxylic acid cycle enzyme mutations and pseudohypoxic signaling in pheochromocytoma and paraganglioma. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1274239"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"101931","DOI":"10.1016\/j.beem.2024.101931","article-title":"MAML3-fusions modulate vascular and immune tumour microenvironment and confer high metastatic risk in pheochromocytoma and paraganglioma","volume":"38","author":"Monteagudo","year":"2024","journal-title":"Best Pr. Res. Clin. Endocrinol. Metab."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0165-4608(89)90091-5","article-title":"Cytogenetic abnormalities in tumors of patients with von Hippel-Lindau disease","volume":"42","author":"Jordan","year":"1989","journal-title":"Cancer Genet. Cytogenet."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1093\/hmg\/ddt069","article-title":"Tumoral EPAS1 (HIF2A) mutations explain sporadic pheochromocytoma and paraganglioma in the absence of erythrocytosis","volume":"22","author":"Bernal","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1158\/0008-5472.CAN-17-2463","article-title":"Germline Mutations in the Mitochondrial 2-Oxoglutarate\/Malate Carrier SLC25A11 Gene Confer a Predisposition to Metastatic Paragangliomas","volume":"78","author":"Buffet","year":"2018","journal-title":"Cancer Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"101416","DOI":"10.1016\/j.beem.2020.101416","article-title":"An overview of 20 years of genetic studies in pheochromocytoma and paraganglioma","volume":"34","author":"Buffet","year":"2020","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2478312","DOI":"10.1080\/07853890.2025.2478312","article-title":"Prognostic significance of Ki-67 in assessing the risk of progression, relapse or metastasis in pheochromocytomas and paragangliomas","volume":"57","author":"Luo","year":"2025","journal-title":"Ann. Med."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Celada, L., Cubiella, T., San-Juan-Guardado, J., Mart\u00ednez, A.S.J., Vald\u00e9s, N., Jim\u00e9nez-Fonseca, P., D\u00edaz, I., Enguita, J.M., Astudillo, A., and \u00c1lvarez-Gonz\u00e1lez, E. (2022). Differential HIF2\u03b1 Protein Expression in Human Carotid Body and Adrenal Medulla under Physiologic and Tumorigenic Conditions. Cancers, 14.","DOI":"10.3390\/cancers14122986"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1530\/ERC-13-0519","article-title":"Overexpression of miR-210 is associated with SDH-related pheochromocytomas, paragangliomas, and gastrointestinal stromal tumours","volume":"21","author":"Tsang","year":"2014","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jss.2019.04.086","article-title":"MicroRNA-210 May Be a Preoperative Biomarker of Malignant Pheochromocytomas and Paragangliomas","volume":"243","author":"Ruff","year":"2019","journal-title":"J. Surg. Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"4946","DOI":"10.7150\/thno.35458","article-title":"Integrative multi-omics analysis identifies a prognostic miRNA signature and a targetable miR-21-3p\/TSC2\/mTOR axis in metastatic pheochromocytoma\/paraganglioma","volume":"9","author":"Calsina","year":"2019","journal-title":"Theranostics"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s12943-018-0876-z","article-title":"Exosomal double-stranded DNA as a biomarker for the diagnosis and preoperative assessment of pheochromocytoma and paraganglioma","volume":"17","author":"Wang","year":"2018","journal-title":"Mol. Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1007\/s40200-024-01466-8","article-title":"The role of methylation quantification of circulating tumor DNA (ctDNA) as a diagnostic biomarker of Pheochromocytomas (PCCs) and Paragangliomas (PGLs)","volume":"23","author":"Khatami","year":"2024","journal-title":"J. Diabetes Metab. Disord."},{"key":"ref_51","unstructured":"Khalil, B., Rosani, A., and Warrington, S.J. (2024, December 11). Physiology, Catecholamines, StatPearls [Internet], Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK507716\/."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1210\/jc.2002-021251","article-title":"A Comparison of biochemical tests for pheochromocytoma: Measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines","volume":"88","author":"Sawka","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Sawka, A.M., Prebtani, A.P., Thabane, L., Gafni, A., Levine, M., and YoungJr, W.F. (2004). A systematic review of the literature examining the diagnostic efficacy of measurement of fractionated plasma free metanephrines in the biochemical diagnosis of pheochromocytoma. BMC Endocr. Disord., 4.","DOI":"10.1186\/1472-6823-4-2"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"111","DOI":"10.14310\/horm.2002.1227","article-title":"Diagnosis of pheochromocytoma with special emphasis on MEN2 syndrome","volume":"8","author":"Pacak","year":"2009","journal-title":"Hormones"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1210\/endrev\/bnae001","article-title":"Imaging of Pheochromocytomas and Paragangliomas","volume":"45","author":"Timmers","year":"2024","journal-title":"Endocr. Rev."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.hoc.2007.04.012","article-title":"Pheochromocytoma: Advances in genetics, diagnosis, localization, and treatment","volume":"21","author":"Mittendorf","year":"2007","journal-title":"Hematol. Clin. N. Am."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S0022-5347(05)68171-2","article-title":"von Recklinghausen\u2019s disease and pheochromocytomas","volume":"162","author":"Walther","year":"1999","journal-title":"J. Urol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1056\/NEJM200205093461911","article-title":"Pheochromocytoma\u2014Death of an Axiom","volume":"346","author":"Dluhy","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/cen.13163","article-title":"Pheochromocytoma and paraganglioma in patients with neurofibromatosis type 1","volume":"86","author":"Gruber","year":"2016","journal-title":"Clin. Endocrinol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1210\/jc.2005-1862","article-title":"Clinical presentation and penetrance of pheochromocytoma\/paraganglioma syndromes","volume":"91","author":"Benn","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1056\/NEJMra1806651","article-title":"Pheochromocytoma and Paraganglioma","volume":"381","author":"Neumann","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1097\/HJH.0000000000002438","article-title":"Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: A position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension","volume":"38","author":"Lenders","year":"2020","journal-title":"J. Hypertens."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"A43","DOI":"10.1097\/00000542-198209001-00043","article-title":"A prospective randomized trial of four anesthetic techniques for resection of pheochromocytoma","volume":"57","author":"Roizen","year":"1982","journal-title":"Anesthesiology"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1210\/clinem\/dgz188","article-title":"Efficacy of \u03b1-blockers on hemodynamic control during pheochromocytoma resection: A Randomized controlled trial","volume":"105","author":"Buitenwerf","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_65","unstructured":"Mariani-Costantini, R. (2019). Surgical and Pharmacological Management of Functioning Pheochromocytoma and Paraganglioma. Paraganglioma: A Multidisciplinary Approach [Internet], Codon Publications. Chapter 4."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijsu.2017.08.026","article-title":"Perioperative hemodynamics and outcomes of patients on metyrosine undergoing resection of pheochromocytoma or paraganglioma","volume":"46","author":"Butz","year":"2017","journal-title":"Int. J. Surg."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1055\/s-0032-1306294","article-title":"High incidence of cardiovascular complications in pheochromocytoma","volume":"44","author":"Zelinka","year":"2012","journal-title":"Horm. Metab. Res."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Y-Hassan, S., and Falhammar, H. (2020). Cardiovascular Manifestations and Complications of Pheochromocytomas and Paragangliomas. J. Clin. Med., 9.","DOI":"10.3390\/jcm9082435"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1007\/s40618-021-01649-7","article-title":"Protocol for presurgical and anesthetic management of pheochromocytomas and sympathetic paragangliomas: A multidisciplinary approach","volume":"44","author":"Chavez","year":"2021","journal-title":"J. Endocrinol. Investig."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1210\/jc.2009-1051","article-title":"Risk factors for hemodynamic instability during surgery for pheochromocytoma","volume":"95","author":"Bruynzeel","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1245\/s10434-014-3847-7","article-title":"Predictors of hemodynamic instability during surgery for pheochromocytoma","volume":"21","author":"Kiernan","year":"2014","journal-title":"Ann. Surg. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/iju.13864","article-title":"Incidence and predictive factors of hypoglycemia after pheochromocytoma resection","volume":"26","author":"Araki","year":"2018","journal-title":"Int. J. Urol."},{"key":"ref_73","unstructured":"Kamath, A.S., and Singh, K. (2023, July 06). Perioperative Management of Pheochromocytoma, StatPearls [Internet], Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK589634\/."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"4069","DOI":"10.1210\/jc.2007-1720","article-title":"Preoperative Management of the pheochromocytoma patient","volume":"92","author":"Pacak","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1053\/j.jvca.2017.02.023","article-title":"Perioperative Management of Pheochromocytoma","volume":"31","author":"Naranjo","year":"2017","journal-title":"J. Cardiothorac. Vasc. Anesth."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1093\/bja\/86.5.731","article-title":"Haemodynamic changes during retroperitoneoscopic adrenalectomy for phaeochromocytoma","volume":"86","author":"Atallah","year":"2001","journal-title":"Br. J. Anaesth."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"bvac004","DOI":"10.1210\/jendso\/bvac004","article-title":"Perioperative Management of Pheochromocytomas and Sympathetic Paragangliomas","volume":"6","author":"Fagundes","year":"2022","journal-title":"J. Endocr. Soc."},{"key":"ref_78","unstructured":"Hines, R.L., and Marschall, K.E. (2018). Endocrine disease. Stoelting\u2019s Anesthesia and Co-Existing Disease, Elsevier. [7th ed.]."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1158\/1078-0432.CCR-20-3703","article-title":"High-Specific-Activity-131I-MIBG versus 177Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and Paraganglioma","volume":"27","author":"Jha","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s12149-022-01798-6","article-title":"Prognostic value of [18F]FDG-PET prior to [131I]MIBG treatment for pheochromocytoma and paraganglioma (PPGL)","volume":"37","author":"Takenaka","year":"2023","journal-title":"Ann. Nucl. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1002\/ijc.28913","article-title":"SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma","volume":"135","author":"Hadoux","year":"2014","journal-title":"Int. J. Cancer"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"101116","DOI":"10.1016\/j.currproblcancer.2024.101116","article-title":"Management of metastatic pheochromocytomas and paragangliomas: When and what","volume":"51","author":"Sukrithan","year":"2024","journal-title":"Curr. Probl. Cancer"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"TPS4191","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS4191","article-title":"Alliance A021804: A prospective, multi-institutional phase II trial evaluating temozolomide versus temozolomide and olaparib for advanced pheochromocytoma and paraganglioma","volume":"41","author":"Perez","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1159\/000499497","article-title":"Peptide Receptor Radionuclide Therapy as a Novel Treatment for Metastatic and Invasive Phaeochromocytoma and Paraganglioma","volume":"109","author":"Mak","year":"2019","journal-title":"Neuroendocrinology"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Kolasinska-\u0106wik\u0142a, A., P\u0119czkowska, M., \u0106wik\u0142a, J.B., Micha\u0142owska, I., Pa\u0142ucki, J.M., Bodei, L., Lewczuk-My\u015blicka, A., and Januszewicz, A. (2019). A Clinical Efficacy of PRRT in Patients with Advanced, Nonresectable, Paraganglioma-Pheochromocytoma, Related to SDHx Gene Mutation. J. Clin. Med., 8.","DOI":"10.3390\/jcm8070952"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1530\/EC-20-0292","article-title":"177Lu-DOTATATE therapy in metastatic\/inoperable pheochromocytoma-paraganglioma","volume":"9","author":"Jaiswal","year":"2020","journal-title":"Endocr. Connect."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1210\/clinem\/dgad166","article-title":"Metastatic Pheochromocytoma and Paraganglioma: Somatostatin Receptor 2 Expression, Genetics, and Therapeutic Responses","volume":"108","author":"Fischer","year":"2023","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Gubbi, S., Al-Jundi, M., Del Rivero, J., Jha, A., Knue, M., Zou, J., Turkbey, B., Carrasquillo, J.A., Lin, E., and Pacak, K. (2021). Case Report: Primary Hypothyroidism Associated With Lutetium 177-DOTATATE Therapy for Metastatic Paraganglioma. Front. Endocrinol., 11.","DOI":"10.3389\/fendo.2020.587065"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1055\/s-0029-1220687","article-title":"Novel and evolving therapies in the treatment of malignant phaeochromocytoma: Experience with the mTOR inhibitor everolimus (RAD001)","volume":"41","author":"Druce","year":"2009","journal-title":"Horm. Metab. Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e600","DOI":"10.1210\/clinem\/dgae283","article-title":"Clinical Activity of Selpercatinib in RET-mutant Pheochromocytoma","volume":"110","author":"Konda","year":"2025","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_91","unstructured":"(2025, May 15). Belzutifan\/MK-6482 for the Treatment of Advanced Pheochromocytoma\/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2\u03b1 Related Genetic Alterations (MK-6482-015), Available online: https:\/\/clinicaltrials.gov\/study\/NCT04924075."},{"key":"ref_92","unstructured":"(2025, June 18). FDA Approves Merck\u2019s WELIREG (Belzutifan) for the Treatment of Adults and Pediatric Patients 12 Years and Older with Locally Advanced, Unresectable, or Metastatic Pheochromocytoma or Paraganglioma (PPGL). Available online: https:\/\/www.merck.com\/news\/fda-approves-mercks-welireg-belzutifan-for-the-treatment-of-adults-and-pediatric-patients-12-years-and-older-with-locally-advanced-unresectable-or-metastatic-pheochromocytoma-or-par\/."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Comandone, A., Vana, F., Comandone, T., and Tucci, M. (2021). Antiangiogenic Therapy in Clear Cell Renal Carcinoma (CCRC): Pharmacological Basis and Clinical Results. Cancers, 13.","DOI":"10.3390\/cancers13235896"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S0140-6736(23)02554-0","article-title":"Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: Results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial","volume":"403","author":"Baudin","year":"2024","journal-title":"Lancet"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/S1470-2045(24)00133-5","article-title":"Cabozantinib in patients with unresectable and progressive metastatic phaeochromocytoma or paraganglioma (the Natalie Trial): A single-arm, phase 2 trial","volume":"25","author":"Jimenez","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s12020-017-1359-5","article-title":"Phase II trial of pazopanib in advanced\/progressive malignant pheochromocytoma and paraganglioma","volume":"57","author":"Jasim","year":"2017","journal-title":"Endocrine"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1055\/a-0715-1888","article-title":"Metastatic Phaeochromocytoma: Spinning Towards More Promising Treatment Options","volume":"127","author":"Grossman","year":"2019","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"13942","DOI":"10.1002\/cam4.6010","article-title":"Management of pheochromocytomas and paragangliomas: Review of current diagnosis and treatment options","volume":"12","author":"Eid","year":"2023","journal-title":"Cancer Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"278","DOI":"10.7150\/thno.77918","article-title":"Epigenetic drugs in somatostatin type 2 receptor radionuclide theranostics and radiation transcriptomics in mouse pheochromocytoma models","volume":"13","author":"Ullrich","year":"2023","journal-title":"Theranostics"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1002\/cncr.35426","article-title":"Role of epigenetic regulation on catecholamine synthesis in pheochromocytoma and paraganglioma","volume":"130","author":"Kaplinsky","year":"2024","journal-title":"Cancer"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1089\/cbr.2020.4633","article-title":"Potential for Increasing Uptake of Radiolabeled 68Ga-DOTATOC and 123I-MIBG in Patients with Midgut Neuroendocrine Tumors Using a Histone Deacetylase Inhibitor Vorinostat","volume":"36","author":"Pollard","year":"2021","journal-title":"Cancer Biotherapy Radiopharm."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1677\/ERC-10-0090","article-title":"Increased uptake of [\u00b9\u00b2\u00b3I]meta-iodobenzylguanidine, [\u00b9\u2078F]fluorodopamine, and [\u00b3H]norepinephrine in mouse pheochromocytoma cells and tumors after treatment with the histone deacetylase inhibitors","volume":"18","author":"Martiniova","year":"2011","journal-title":"Endocr Relat Cancer"},{"key":"ref_103","first-page":"211","article-title":"Histone deacetylase inhibitors as a novel therapeutic approach for pheochromocytomas and paragangliomas","volume":"30","author":"Manta","year":"2022","journal-title":"Oncol. Res. Featur. Preclin. Clin. Cancer Ther."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Uher, O., Vanova, K.H., Lencova, R., Frejlachova, A., Wang, H., Zhuang, Z., Zenka, J., and Pacak, K. (2021). Identification of Immune Cell Infiltration in Murine Pheochromocytoma during Combined Mannan-BAM, TLR Ligand, and Anti-CD40 Antibody-Based Immunotherapy. Cancers, 13.","DOI":"10.3390\/cancers13163942"},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Senders, Z.J., and Martin, R.C.G. (2022). Intratumoral Immunotherapy and Tumor Ablation: A Local Approach with Broad Potential. Cancers, 14.","DOI":"10.3390\/cancers14071754"},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Lookian, P.P., Zhao, D., Medina, R., Wang, H., Zenka, J., Gilbert, M.R., Pacak, K., and Zhuang, Z. (2021). Mannan-BAM, TLR Ligands, Anti-CD40 Antibody (MBTA) Vaccine Immunotherapy: A Review of Current Evidence and Applications in Glioblastoma. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22073455"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Jimenez, C., Armaiz-Pena, G., Dahia, P.L.M., Lu, Y., Toledo, R.A., Varghese, J., and Habra, M.A. (2022). Endocrine and Neuroendocrine Tumors Special Issue\u2014Checkpoint Inhibitors for Adrenocortical Carcinoma and Metastatic Pheochromocytoma and Paraganglioma: Do They Work?. Cancers, 14.","DOI":"10.3390\/cancers14030467"},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Jimenez, C., Subbiah, V., Stephen, B., Ma, J., Milton, D., Xu, M., Zarifa, A., Akhmedzhanov, F.O., Tsimberidou, A., and Habra, M.A. (2020). Phase II Clinical Trial of Pembrolizumab in Patients with Progressive Metastatic Pheochromocytomas and Paragangliomas. Cancers, 12.","DOI":"10.3390\/cancers12082307"},{"key":"ref_109","unstructured":"Colby, C. (2025, June 18). Another Car T-Cell Clinical Trial Open to Neuroendocrine Cancer Patients. Available online: https:\/\/netrf.org\/2024\/08\/21\/another-car-t-cell-clinical-trial-open-to-neuroendocrine-cancer-patients\/#:~:text=CAR%20T-cell%20therapies%20work,Adrenocortical%20Carcinoma."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"106701","DOI":"10.1016\/j.phrs.2023.106701","article-title":"Oncolytic adenovirus-mediated expression of CCL5 and IL12 facilitates CA9-targeting CAR-T therapy against renal cell carcinoma","volume":"189","author":"Fang","year":"2023","journal-title":"Pharmacol. Res."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Ronca, R., and Supuran, C.T. (2024). Carbonic anhydrase IX: An atypical target for innovative therapies in cancer. Biochim. et Biophys. Acta (BBA) Rev. Cancer, 1879.","DOI":"10.1016\/j.bbcan.2024.189120"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/13\/6080\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:58:07Z","timestamp":1760032687000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/13\/6080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,25]]},"references-count":111,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["ijms26136080"],"URL":"https:\/\/doi.org\/10.3390\/ijms26136080","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,25]]}}}